Deletion 1p36 syndrome is recognized as the most common terminal deletion syndrome. Here, we describe the loss of a gene within the deletion that is responsible for the cardiomyopathy associated with monosomy 1p36, and we confirm its role in nonsyndromic left ventricular noncompaction cardiomyopathy (LVNC) and dilated cardiomyopathy (DCM). With our own data and publically available data from array comparative genomic hybridization (aCGH), we identified a minimal deletion for the cardiomyopathy associated with 1p36del syndrome that included only the terminal 14 exons of the transcription factor PRDM16 (PR domain containing 16), a gene that had previously been shown to direct brown fat determination and differentiation. Resequencing of PRDM16 in a cohort of 75 nonsyndromic individuals with LVNC detected three mutations, including one truncation mutant, one frameshift null mutation, and a single missense mutant. In addition, in a series of cardiac biopsies from 131 individuals with DCM, we found 5 individuals with 4 previously unreported nonsynonymous variants in the coding region of PRDM16. None of the PRDM16 mutations identified were observed in more than 6,400 controls. PRDM16 has not previously been associated with cardiac disease but is localized in the nuclei of cardiomyocytes throughout murine and human development and in the adult heart. Modeling of PRDM16 haploinsufficiency and a human truncation mutant in zebrafish resulted in both contractile dysfunction and partial uncoupling of cardiomyocytes and also revealed evidence of impaired cardiomyocyte proliferative capacity. In conclusion, mutation of PRDM16 causes the cardiomyopathy in 1p36 deletion syndrome as well as a proportion of nonsyndromic LVNC and DCM.

Introduction

Chromosome 1p36 deletion syndrome (MIM 607872) is the most common human terminal deletion syndrome, occurring in 1 out of 5,000 births.1 Among the major characteristics of the syndrome are craniofacial dysmorphism, structural brain abnormalities, seizure disorder, hearing loss, intellectual disability, and growth delay.2–4 A substantial proportion (23%–27%) of individuals with 1p36 deletion syndrome have cardiomyopathy, which may occur in the presence or absence of structural heart disease.3,4 In a systematic clinical and molecular characterization of a 1p36 deletion syndrome cohort, left ventricular noncompaction (LVNC [MIM 604169]) was identified in 23% and dilated cardiomyopathy (DCM [MIM 115200]) in 4% of individuals.4 LVNC is a common feature in early embryopathy in humans and in rodent models and is characterized by a two-layered myocardium consisting of a thin compacted epicardial layer and a thick noncompacted endocardial layer with numerous prominent ventricular trabeculations and deep intertrabecular recesses.5 It can be associated with increased ventricular chamber dimensions and impaired systolic function, which are cardinal features of DCM. Both LVNC and DCM are genetically heterogeneous, with mutations in genes encoding sarcomeric, cytoskeletal, mitochondrial, and calcium handling proteins causing either phenotype.6 Clinical features of both cardiomyopathies include progressive deterioration in cardiac function that results in heart failure, arrhythmias, and sudden cardiac death. Loss or disruption of a gene


1Department of Congenital Heart Disease and Pediatric Cardiology, University Hospital of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany; 2Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, and Harvard Stem Cell Institute, Boston, MA 02115, USA; 3Max-Delbrück-Center for Molecular Medicine (MDC), 13125 Berlin, Germany; 4Institute of Human Genetics, Christian-Albrechts-University Kiel & University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany; 5Institute of Medical Genetics and Human Genetics, Charité University Medicine Berlin, 13353 Berlin, Germany; 6Institute of Human Genetics, University Würzburg, 97074 Würzburg, Germany; 7Department of Computational Biology, Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany; 8Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA; 9Department of Pathology, German Heart Institute Berlin, 13353 Berlin, Germany; 10Experimental and Clinical Research Center (ECRC), Charité Medical Faculty and Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; 11National Heart and Lung Institute, Imperial College, London SW7 2AZ, UK; 12NIHR Royal Brompton Cardiovascular Biomedical Research Unit, London SW3 6NP, UK; 13Cardiovascular Center, University Hospital Zurich, 8001 Zurich, Switzerland; 14Department of Congenital Heart Defects & Pediatric Cardiology, German Heart Institute Berlin, 13353 Berlin, Germany; 15Department of Pediatric Cardiology, Charité University Medicine Berlin, 13353 Berlin, Germany; 16DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Germany; 17National Heart Centre, Singapore 168752, Singapore; 18Duke-NUS Graduate Medical School, Singapore 169857, Singapore
19These authors contributed equally to this work
*Correspondence: klaassen@mdc-berlin.de
http://dx.doi.org/10.1016/j.ajhg.2013.05.015. ©2013 by The American Society of Human Genetics. All rights reserved.
responsible for the cardiomyopathy in individuals with monosomy 1p36 has not previously been identified.

We present detailed multiallelic mapping in the 1p36 deletion syndrome that identifies loss of PRDM16 (MIM 605557) as underlying the cardiomyopathy in this syndrome. We independently confirm a causal role for PRDM16 in human myocardial disease in two separate cohorts: one with nonsyndromic LVNC and one with simplex cases of dilated cardiomyopathy (DCM). We are able to recapitulate biological features of human cardiomyopathy in the zebrafish by modeling of both PRDM16 haploinsufficiency and a human truncation mutant. This modeling implicates impaired proliferative capacity during cardiogenesis as a primary mechanism of these inherited forms of heart failure caused by PRDM16 mutations.

Material and Methods

Comparative Genomic Hybridization
Genomic imbalances were analyzed by array comparative genomic hybridization (aCGH) with different oligonucleotide platforms (Agilent Technologies) at the Charité University Hospital Berlin and University Hospital Schleswig-Holstein, Kiel. Further genomic and phenotypic data from probands with monosomy 1p36 (Tables S1 and S2 available online) were extracted from the following databases: Decipher, ECARUCA database, NCBI, and Genoglyphix. Genomic positions in the text are cited according to the reference human genome (UCSC Genome Browser GRCh37/hg19) (Table S1).

Study Participants and Clinical Evaluation
A total of 206 probands with nonsyndromic cardiomyopathy were recruited at tertiary referral centers, the Charité University Hospital and the German Heart Institute (both in Berlin, Germany), the University Hospital Zürich (Switzerland), and the Harefield Hospital (Harefield, UK). Informed consent was obtained from all participants according to institutional guidelines. Probands and available family members were clinically evaluated as described previously. LVNC and DCM were diagnosed on the basis of established criteria. A total of 75 individuals with LVNC were studied and only LVNC probands without a known mutation in genes encoding sarcomere proteins were enrolled in the study. In 56/75 probands, no mutations had been detected and 19/75 probands had not been tested. In 11/75 LVNC probands, at least one more first-degree relative had been clinically diagnosed to be affected but not all first-degree family members were systematically available and could be investigated. For RNA-seq studies, 131 explanted heart biopsies samples from individuals with confirmed DCM undergoing heart transplantation were used with local ethical approval. From probands with DCM, the family history and the number of familial or simplex cases was unknown and they had not been screened for mutations in genes encoding sarcomere proteins.

Mutational Analysis
PCR and Sanger sequencing of PRDM16 (RefSeq accession number NM_022114.3) in probands with LVNC or DCM and of SKI (MIM 164780 [RefSeq NM_003036.3]) in probands with LVNC were performed by standard methods. Primer sequences and PCR details are available on request. Sequences were analyzed with Sequencher 4.10.1 (Gene Codes Corporation). In the 131 DCM individuals, poly(A) RNA was sequenced on the Illumina HiSeq 2000 platform with TruSeq library preparation and 2 × 100 bp paired-end sequencing chemistry. Reads were mapped stringently against the hg19 reference genome with TopHat 1.3.1, allowing only a total of 2 mismatches in 100 bp and supplying transcript information as annotated by the Ensembl database to aid the mapping process. SNP calling in the coding region of PRDM16 was performed with SAMtools only with reads mapping uniquely to the genome. Genomic positions covered with more than 15 unique reads (no PCR duplicates) were considered for SNP detection.

Immunofluorescence Staining and Microscopy
Paraffin sections of 19-week-old fetal and adult human left ventricular myocardium (48-year-old male individual as donor for heart transplantation; cause of death was subarachnoid hemorrhage) and wild-type embryonic mouse hearts (13.5 dpc) were deparaffinized and rehydrated and heat-mediated antigen retrieval was performed in sodium citrate buffer (10 mM [pH 6.0]) for 20 min. Sections were allowed to cool to room temperature before blocking in antibody solution containing 5% normal goat serum for 1 hr. For staining of adult mouse hearts, cryosections of fresh frozen cardiac tissue were used after 20 min postfixation in 4% PFA. Primary antibodies were applied at 4°C overnight, sections were washed three times in PBS, and secondary antibody detection was performed at room temperature for 1 hr with Alexa 488 or Alexa 555 goat anti-rabbit or goat anti-mouse antibodies (Invitrogen). Nuclei were stained with TO-PRO-3 or DAPI (Invitrogen) and sections were mounted in Prolong Gold antifade reagent (Invitrogen). The primary antibodies used were rabbit anti-PRDM16 (Abcam) and mouse anti-Troponin T (Developmental Studies Hybridoma Bank at the University of Iowa). For staining cell membranes, FITC-conjugated wheat germ agglutinin (WGA) was used while endocardial cells were stained with FITC-conjugated Isolecitin B4 (Enzo Life Sciences), both of which were incubated together with the primary antibody at 4°C overnight. The specificity of PRDM16 staining was tested by preincubating the primary PRDM16 antibody with the respective immunizing peptide (Acris Antibodies) at 4°C overnight prior to the immunofluorescence procedure. Images were taken with a Leica SPS confocal laser-scanning microscope.

Zebrafish Studies
Morpholino Antisense Oligonucleotide Injections
Antisense morpholinos were injected as described at the one-cell stage. Concentrations of 0.2 mM were used; for synergistic experiments the concentration was reduced to 0.1 mM. Embryos were then analyzed at 24, 48, and 72 hr postfertilization (hpf). Morpholinos directed against the translation start codon were 5′-TACCTCGTCTTCCGGCTCCTGCT-3′ for prdm16, 5′-TAATACTGATGTCTTACACTTCCCTCT-3′ for pumbl mismatch control, and the splice donor site of exon 2 5′-TGCTCTCC TCCCCATCTGTTCCTCCCT-3′ for skia (RefSeq NM_130935.2). Morpholinos were purchased from Gene Tools.

Cardiac Overexpression
For cardiac-specific overexpression experiments, the human PRDM16 truncation mutation (c.2104A>T [p.Lys702*]) and the human PRDM16 wild-type were cloned downstream of the cmrlc2 promoter into the Tol2kit expression system by Gateway
technology (Invitrogen). We co-injected the PRDM16 constructs (15 ng/ul) with 10 ng/ul capped Tol2 transposase mRNA into one-cell-stage zebrafish embryos.

**Rescue Experiments**

To rescue the cardiac phenotype, different doses of human wild-type mRNA were co-injected with either PRDM16 morpholino or PRDM16 truncation construct into the one-cell-stage zebrafish embryo.

**Zebrafish Physiologic Analysis**

For analysis of cardiac function, embryos were laterally positioned and allowed to acclimate at 24°C. Video microscopy was performed on an Axioplan (Zeiss) upright microscope with a FastCam-PCI high-Speed digital camera (Photron) on top. A total of 1,088 frames were digitally captured at identical frame rates (250 frames per second) and magnification (5x). Sequential images were analyzed for heart rate and cardiac output with IMAGEJ and Excel. Experiments were repeated at least three times on each occasion with ten animals.

Intercellular coupling parameters in zebrafish embryo hearts were measured by previously reported techniques. In brief, hearts were isolated from zebrafish embryos, stained with the transmembrane-potential-sensitive dye di-8-ANEPPS (Invitrogen), and placed into a perfusion chamber that was mounted onto the stage of an inverted microscope. Excitation light from a high-intensity Hg arc lamp was transmitted through a 525/50 nm bandpass filter and reflected onto the preparation via a 565 nm dichroic mirror. Fluorescence emission was filtered by a 685/80 nm bandpass filter and recorded at a rate of 2,000 s⁻¹ by a high-speed CCD camera (CardioCCD-SMQ, RedshirtImaging, LLC). Single-pixel action potentials were extracted from the fluorescence data and conduction velocities were estimated by an established algorithm. Experiments were repeated at least two times with five animals.

**RNA In Situ Hybridization, Immunofluorescence, and Detection of Apoptosis**

24-, 48-, and 72-hpf-old zebrafish embryos were used for in situ hybridization carried out by standard protocols with fluorescein-labeled sense and antisense RNA probes for prdm16 (RefSeq XM_01922892.3). For proliferation detection, hearts from 28-, 48-, 72-, and 96-hpf-old zebrafish embryos were isolated and fixed in Prefer fixative (Anatech). The fixed hearts were stained with the primary antibodies rabbit anti-PCNA 1:200 (Abcam) and mouse anti-MF20 1:100 (DSHB) and with the secondary antibodies donkey or goat anti-rabbit or mouse Alexa 488 or 546 conjugated (Invitrogen) 1:1,000. Hearts were mounted with ProLong Antifade reagent with DAPI mounting medium on a slide. Confocal images were analyzed with IMAGEJ.

For detection of apoptosis, hearts from 48-, 72-, and 96-hpf-old zebrafish embryos were used for in situ hybridization carried out by standard protocols with fluorescein-labeled sense and antisense RNA probes for prdm16 (RefSeq XM_01922892.3).

**Statistical Analysis**

For functional experiments in zebrafish, one-way ANOVA was used. Fisher’s exact test was used to test the significance of mutational variants found in nonsyndromic LVNC and DCM. Data are presented as means ± SEM. p < 0.05 was considered statistically significant for all tests; *p < 0.05, **p < 0.005, ***p < 0.0005.

**Results**

**Alignment of Regions of Loss in Individuals with 1p36 Deletion Syndrome and Cardiomyopathy**

In order to identify potential candidate genes involved in the pathogenesis of the cardiac phenotypes in chromosome 1p36 deletion syndrome, we aligned the regions of chromosomal loss in individuals with cardiomyopathy from our institutional cohorts and from publicly available databases (Figure 1A). In total, we identified 18 individuals (17 from available databases and 1 from our institution) with a deletion in 1p36 with evidence of heart muscle disease (Figure 1A and Table S1). Various extracardiac phenotypes were present in the 18 individuals with cardiomyopathy, most frequently developmental delay (13/18) and intellectual disability (11/18) (Table S2). With the exception of a single case that had a very large deleted segment (7.2 Mb), all identified individuals shared a minimal region of loss at chr1: 3,224,674–3,354,772 bp (UCSC Genome Browser GRCh37/hg19) that affected only a single gene, PRDM16. In particular, exons 4–17 of PRDM16 were included in the minimal interval, suggesting perturbation of the function of this gene as the cause of the cardiomyopathy in chromosome 1p36 deletion syndrome.

**Identification of PRDM16 Point Mutations in Nonsyndromic Cardiomyopathy**

To independently assess the role of PRDM16 mutations as a genetic cause of cardiomyopathy, we extended our analyses to nonsyndromic forms of both LVNC and DCM. We sequenced the entire coding region of PRDM16 in 75 unrelated individuals of Western European descent (49 men and 26 women; mean age, 43 years; range 0.4 to 78 years) that had previously been diagnosed with LVNC via standard criteria. Heterozygous PRDM16 mutations were identified in 3/75 probands that were not present in 156 in-house control subjects or in the 1000 Genomes Project (p = 0.00021) (Figures 1B, 2, and S1A). The LVNC mutations all resided in the large exon 9 of PRDM16 and included one truncation (c.2104A>T [p.Lys702*]), one frameshift null mutation (c.1573dupC [p.Arg525Profs*79]), and one missense mutation (c.2447A>G [p.Asn816Ser]) affecting an amino acid residue with complete evolutionary conservation to zebrafish. Figure 2 describes the phenotype of three LVNC probands with PRDM16 mutations. To evaluate DCM subjects, we performed RNA-seq on RNA extracted from 131 heart biopsies.
obtained from unrelated individuals with simplex cases of the disorder. This identified four previously unreported nonsynonymous variants in the coding region of PRDM16 in five individuals. These variants were confirmed by Sanger sequencing of genomic DNA from peripheral blood (Figures 1B and S1B). The four identified variants were not listed by the 1000 Genomes Project or detected in the more than 6,400 control individuals of the Exome Sequencing Project (ESP) and were thus considered novel. Considering the prevalence of missense variants in PRDM16 (n = 55 in 6,400 exomes) in the ESP control population, we would expect only ~1.2 novel mutations in a set of 131 individuals. When compared to the novel variants identified from the 6,400 individuals sequenced by ESP, this represents a more than 4-fold enrichment of novel nonsynonymous coding variants (p = 0.006). The significant enrichment of novel nonsynonymous variants affecting PRDM16 in the cohort further supports a role for PRDM16 in DCM. One mutation is located in a zinc finger domain of exon 6 (c.872C>T [p.Pro291Leu]) and three individuals are affected by mutations that disrupt the coding sequence at the C terminus of PRDM16 that mediates the regulation of TGFβ signaling (c.2660T>C [p.Leu887Pro]), of which two share the same mutation (c.3301G>A [p.Val1101Met]) (Table 1). Only the mutation c.811G>A (p.Glu271Lys) is not linked to any known functional domain. All five missense mutations in probands with LVNC and DCM occur at evolutionarily conserved residues (Figure S1B).

Cardiac Localization Profile of PRDM16
To investigate a potential role for alterations in PRDM16 in cardiac structure and function, we first evaluated PRDM16 protein localization in the left ventricle of wild-type mice and in the human heart (Figures 3 and S2). In fetal and adult human heart, PRDM16 was localized in the nuclei of both cardiomyocytes and interstitial cells. At mouse embryonic day 13.5, PRDM16 was localized throughout the ventricular myocardium including endocardium and epicardium. In the adult mouse, PRDM16 localization was predominantly restricted to the nuclei of cardiomyocytes. Taken together, these data support the hypothesis that PRDM16 is expressed in embryonic and adult mammalian left ventricular myocardium. RNA in situ hybridization in zebrafish revealed predominant expression of prdm16 in the brain and heart (Figure S3).
Loss of Function and Mutant Transgenic Analysis in Zebrafish

To examine the effect of PRDM16 mutations, we performed knockdown of the zebrafish ortholog of PRDM16 by using translation-blocking morpholinos to recapitulate potential haploinsufficiency. We also generated fish transgenic for the truncated mutant form of PRDM16 (c.2104A>T [p.Lys702*]) driven by the cardiac-specific cmlc2 promoter. Dose-dependent bradycardia was observed and cardiac output was significantly reduced in both morphant (p < 0.0005) and in truncation mutant transgenics (p < 0.0005) when compared with controls (Figure 4A). Importantly, the contractile impairment in both the morphant knockdown embryos and in the truncation mutant transgenics was efficiently rescued by the wild-type human PRDM16 (Figure S4) in a dose-dependent manner. Notably, to rescue the truncation mutant (Figure S4B), a 10-fold excess of wild-type RNA was necessary compared to the morphant knockdown (Figure S4A).

Semiautomated cell counting documented a significant decrease in total cardiomyocyte numbers in PRDM16 morphant hearts when compared to WT controls (p < 0.05) and PRDM16 WT (p < 0.05) at 48 hpf (Figures 4B and 4C). At 96 hpf, total cardiomyocyte numbers were also decreased in the mutant hearts compared to WT controls (p < 0.005) and PRDM16 WT (p < 0.05) (Figure 4C). This was associated with significantly decreased cardiomyocyte proliferation (percentage of PCNA-positive cells) in the hearts of the morphant (p < 0.0005), the truncation (p < 0.0005), and PRDM16-overexpressing wild-type (p < 0.005) hearts at 28 and 48 hpf (p < 0.0005; p < 0.005; p < 0.005) consecutively (Figures 4B and 4C). Proliferation of control WT decreased over time (28–96 hpf). Interestingly, the effects of mutant and wild-type PRDM16 constructs on proliferation appear to act in opposing directions between 48 or 96 hpf and 72 hpf. In addition, there was evidence of a concomitant increase in apoptosis in the PRDM16 mutants at 48 hpf by using either TUNEL assay (p < 0.005) or annexin V transgenic reporter lines (p < 0.005) (Figure S5).

Proliferation is often reciprocally related to cell coupling. In murine models where LVNC is observed, it has been associated with evidence of partial cellular uncoupling, so we tested the effects of PRDM16 on intercellular impulse propagation across the myocardium, identifying a significant reduction in coupling in morphant and in mutant hearts (Figure 5A). Mean estimated conduction velocities from the outer curvature of the ventricle (OC) confirm a significant reduction in impulse propagation velocities in morphant (p < 0.0005) and mutant (p < 0.0005) hearts when compared with uninjected controls or wild-type (Figure 5B).

 Genetic Interaction of PRDM16 with SKI

The deletion of the TGF-β repressor SKI in individuals with 1p36del syndrome has been hypothesized to contribute to

[Figure 2. Left Ventricular Morphology and Clinical Description of LVNC Probands with PRDM16 Mutations]

(A) Echocardiographic apical 4-chamber view of proband 1 showing involvement of apical and lateral segments. Proband 1 carried a frameshift mutation (c.1573dupC [p.Arg525Profs*79]) and presented at age 33 years with severe biventricular heart failure with systolic and diastolic dysfunction, secondary pulmonary hypertension, and dilatation of both atria and ventricles. He received a biventricular intracardiac defibrillator.

(B) Short axis view of the same proband at the level below the LV papillary muscles showing marked thickening of the inferior noncompacted layer and thinning of the compacted layer.

(C) Echocardiographic apical 4-chamber view of proband 2 showing involvement of the LV midventricular lateral wall. Proband 2, with a truncation mutation (c.2104A>T [p.Lys702*]), was diagnosed at age 12 years because of arrhythmias and showed mild to moderate left ventricular dysfunction and dilatation in addition to LVNC.

(D) Haematoxylin staining of LV myocardium of proband 3. In proband 3 a missense mutation (c.2447A>G [p.Asn816Ser]) was detected. He had been sent to cardiac surgery for the reconstruction of a dysplastic mitral valve at the age of 11 years because of mitral insufficiency grade 3. The left atrium and left ventricle were enlarged with preserved cardiac function. Histology of a left ventricular biopsy taken at cardiac surgery showed increased interstitial fibrosis and myocyte disarray.
some of the associated syndromic features. Indeed, in 14 of 18 probands with a deletion in chromosome 1p36, SKI was deleted in addition to PRDM16 (Table S1). To evaluate this possibility, we screened our independent nonsyndromic LVNC cohort for mutations in SKI, but no mutations were identified. In addition, we tested for genetic interactions between PRDM16 and the zebrafish ortholog of SKI. Coinjection of subthreshold doses of PRDM16 and SKI MOs reduced cardiac output (Figure 5C), suggesting significant functional synergy between these two genes in their effects on contractility (p < 0.0005).

### Discussion

By using existing genomic data, we identified PRDM16 in the region of minimal genomic overlap in individuals with 1p36 deletion syndrome and cardiomyopathy. We went on to identify mutations in PRDM16 in two cohorts of nonsyndromic LVNC and DCM, independently confirming a causal role for the gene in these forms of human myocardial disease. Together these data implicate another pathway in the spectrum of known monogenic causes of heart failure and offer the potential for studies of the mechanisms of this morbid condition and possible therapies.

The 1p36del syndrome is the most common form of large-scale terminal deletion observed in humans. Clearly, the disruption or dose reduction of multiple different genes may contribute to the various phenotypes observed in this syndrome and to the pleiotropic manifestations reported. We focused on the most specific cardiac phenotype present in the individuals with 1p36del syndrome and were able to identify a minimal interval containing only part of a single gene (PRDM16). Several other studies have mapped critical regions within the 1p36 deletion syndrome.21,22 Candidate genes for features of 1p36del syndrome, including facial clefting anomalies (SKI), seizures (KCNAB2 [MIM 601142]), and cranial suture closure (MMP23 A/B [MIM 603320 and 603321]), have been proposed. Gajecka et al. suggested five candidate genes, among them PRDM16, that might contribute to the phenotypic feature of LVNC. PRDM16 was anticipated to play a role in heart development because mutant mice had gross cardiac ventricular hypoplasia.26

Mutations in SKI have recently been shown to cause Shprintzen-Goldberg syndrome (MIM 182212) with aortic aneurysm and a role for SKI in early cardiovascular development has been proposed.27,28 Our observation that loss of function of both SKI and PRDM16 act synergistically would support the interaction with SKI as a potential mechanism in some of the known deletions. In 14 of our 18 probands with a deletion in chromosome 1p36, SKI was deleted in addition to PRDM16. Although there were no obvious phenotypic differences between probands with or without a deletion of SKI, our studies raise the possibility of a modifier effect of SKI in the 1p36del syndrome. All but one (case 16, arr CGH 1p36(5,400,000–12,700,000)×1) (Table S1) of the individuals with 1p36del syndrome were hemizygous for PRDM16. Though knockdown of PRDM16 and the single PRDM16 truncation mutant appear equivalent in our zebrafish model, it is certainly possible that perturbation or dose reduction of other genes and/or a long-range regulatory effect within the interval contribute to the cardiac phenotypes observed. Monosomy 1p36 may not be a simple contiguous gene deletion syndrome and deletions of variable size may account for the characteristic phenotype by position effect on one or more genes along the 1p36 region. Several hypotheses have been formed, following the description of different chromosomal rearrangements occurring next to variants in genes that cause human developmental disorders. In case 16, it is unknown whether a position effect would be possible because the distal deletion breakpoint is not adjacent to PRDM16, being ~2 Mb (2,044,815 bp) away from the proximal boundary of PRDM16. Case 16 was taken from a publicly available database. Neither PRDM16 nor SKI were deleted and we could not rule out possible mutations in these genes. Other possibilities are that this individual represents a

<table>
<thead>
<tr>
<th>Disease</th>
<th>Variant</th>
<th>Nucleotide Change</th>
<th>Exon</th>
<th>SIFT*</th>
<th>PolyPhen-2®</th>
<th>Sequence Features (Uniprot)</th>
<th>Affected Individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVNC</td>
<td>p.Lys702*</td>
<td>c.2104A</td>
<td>9</td>
<td>0.23</td>
<td>0.196</td>
<td>–</td>
<td>1</td>
</tr>
<tr>
<td>LVNC</td>
<td>p.Lys702*</td>
<td>c.2104A</td>
<td>9</td>
<td>0.23</td>
<td>0.196</td>
<td>–</td>
<td>1</td>
</tr>
<tr>
<td>LVNC</td>
<td>p.Lys702*</td>
<td>c.2104A</td>
<td>9</td>
<td>0.23</td>
<td>0.196</td>
<td>–</td>
<td>1</td>
</tr>
<tr>
<td>DCM</td>
<td>p.Val1101Met</td>
<td>c.3301G&gt;A</td>
<td>15</td>
<td>0.15</td>
<td>0.46</td>
<td>mediates interaction with SKI and regulation of TGF-β signaling</td>
<td>2</td>
</tr>
</tbody>
</table>

Abbreviations are as follows: LVNC, left ventricular noncompaction; DCM, dilated cardiomyopathy.

*Scores less than 0.05 indicate substitutions are predicted as intolerant.

**Scores are evaluated as 0.000 (most probably benign) to 0.999 (most probably damaging).
phenocopy and that another locus than the one on chromosome 1p36 or a nongenetic etiology is responsible for this person’s cardiomyopathy.

Notably, the 1p36del syndrome exhibits gender bias, raising the possibilities of a sex-linked modifier or of some form of imprinting. Out of 18 individuals with 1p36del syndrome reported in this study, 16 were females. Further work in zebrafish and extent murine models will help to clarify the mechanistic basis of this effect.

LVNC has recently been classified as a distinct primary cardiomyopathy with a genetic etiology. Mutations in genes encoding sarcomere proteins account for 30% of cases of isolated, nonsyndromic LVNC. LVNC is seen in a number of genetic syndromes, and like DCM has been associated with neuromuscular disorders such as dystrophinopathies and with mitochondrial disease. Many individuals with 1p36del syndrome that have been published in small and large studies are deleted for this region but do not have any features of LVNC. This observation is in accordance with the observation that incomplete penetrance is a hallmark of the cardiomyopathic phenotypes. Diagnosis is mostly made by echocardiography, and in previously studied cohorts some asymptomatic individuals with 1p36del syndrome with mild LVNC or DCM may not have been recognized.

There appears to be a correlation between the size of the deletion and severity of some clinical features although there is no correlation between the deletion size and number of observed clinical features. Even individuals with deletions <3 Mb can present with most of the features associated with monosomy 1p36. Individuals with overlapping or even identical regions of deletion demonstrate variable expression of the phenotype. In a case of recurrent monosomy 1p36 observed in siblings secondary to potential germline mosaicism, LVNC was present in both individuals with different severity of the disease. Whereas the one individual showed signs of mild left ventricular dysfunction with DCM that required anticongestive heart failure treatment, the cardiomyopathy of the sibling remained clinically silent. Although these cases share the same underlying molecular etiology of the cardiomyopathic phenotypes, interactions of genetic etiology, background modifier genes, and/or hemodynamic factors most probably contribute to the development of the phenotype.
PRDM16 acts as a transcription factor with zinc finger DNA-binding domains and positive regulatory (PR), repressor, and acidic domains. PRDM16 regulates leukemogenesis, palatogenesis, neurogenesis, and brown fat development. Chromosomal translocations resulting in increased expression of isoforms of PRDM16 that lack the PR domain are found recurrently in myelodysplastic syndrome and acute myeloid leukemias. PRDM16 has been shown to direct brown fat determination and differentiation by forming a transcriptional complex with the active form of C/EBP-β and acting as a critical complex in the control of the cell fate switch from myoblastic precursors to brown fat cells. PRDM16 has also been described to have a regulatory role in transforming growth factor (TGF)-β signaling. A negative effect of PRDM16 on TGF-β signaling has been demonstrated in vitro and activated or repressed levels of activity in vivo may disrupt the delicate balance between cell proliferation and differentiation.

Interestingly, PRDM16 has a dominant-positive effect on cardiomyocyte proliferation in zebrafish where either activated or repressed levels of activity of PRDM16 impair cardiomyocyte proliferation (Figure 4C). This reduction in cell number appears to result from a combination of diminished proliferation and increased apoptosis, possibly through effects mediated via TGF-β signaling or interaction with C/EBP-β. We noted distinctive effects on subsequent waves of cardiomyocyte proliferation, suggesting that mutant and wild-type PRDM16 are acting in opposite directions, possibly as a result of differential interaction with developmental partners during the serial waves of proliferation in the developing heart.

Perturbation of intercellular coupling can lead to cardiomyopathy and has also been implicated in the regulation of cardiomyocyte differentiation. Specific mutants in cardiac desmosomal genes have suggested abnormalities along the spectrum of differentiation between adipocyte and myocyte and, together with the discovery of PRDM16 mutations, implicate a complex role for electrical or mechanical refinement of a basic transcriptional program in refining myocardial differentiation. PRDM16 has been implicated in the myocyte-adipocyte fate switch.

Figure 4. PRDM16 Knockdown and Human PRDM16 Truncation Mutant in a Zebrafish Model
(A) There is significantly reduced heart rate and cardiac output in PRDM16 MO and PRDM16 mutant animals compared to WT, MO control, and PRDM16 WT.
(B) In PRDM16 MO and PRDM16 mutant hearts, there is significant reduction in total cell number and rates of cellular proliferation at 48 hpf that is only partially rescued by PRDM16 WT overexpression.
(C) Time-dependent effect of PRDM16 on cell number and proliferation in WT, PRDM16 MO, PRDM16 mutant, and PRDM16 WT embryos. Plotting cell number during cardiac development reveals that both morphant and mutant fish exhibit reduced cell numbers that despite changes in proliferation rates are not fully recovered by 96 hpf. The effects of mutant and wild-type PRDM16 constructs appear to act in opposing directions between 48 or 96 hpf and 72 hpf. The mechanism for this effect is unknown but is not related to changes in the baseline expression of PRDM16.

One-way ANOVA test: *p < 0.05; **p < 0.005; ***p < 0.0005. The error bars represent the mean ± SEM.
in skeletal muscle, and the loss of coupling that characterizes more adipogenic fates may underlie the profound effects we have observed with PRDM16 knockdown or mutation. The highly orchestrated myocardial coupling evident in the later stages of cardiogenesis may require a critical mass of cardiomyocytes or a critical physiologic stimulus. In addition, the emerging role of epigenetic factors in refining cardiac development, modulating cardiomyocyte differentiation, and establishing definitive cardiac structure and function suggests that there is likely to be complex interplay among these various mechanisms. Interestingly, PRDM16 helps maintain the integrity of mammalian heterochromatin and the structure of the nuclear lamina. Understanding the reduced stimulus or its transduction failure will provide a unifying framework for the analysis of a wide range of human conditions and animal model phenotypes associated with cardiomyopathy.

In conclusion, we show that mutation of the transcription factor PRDM16 is an important cause of cardiomyopathy in individuals with the chromosome 1p36 deletion syndrome as well as in nonsyndromic forms of LVNC and DCM. Our functional studies implicate impaired proliferative capacity during cardiogenesis as a primary mechanism of these PRDM16-related cardiomyopathies and suggest a pathway in human heart failure that may be amenable to therapeutic intervention.

Supplemental Data

Supplemental Data include five figures and two tables and can be found with this article online at http://www.cell.com/AJHG/.

Acknowledgments

This study makes use of data generated by the DECIPHER Consortium. A full list of centers that contributed to the generation
of the data is available from http://decipher.sanger.ac.uk and via email from decipher@sanger.ac.uk and funding of the project was provided by the Wellcome Trust. We are pleased to cite the database Ecaruca for cytogenetic information. We are grateful to L. Thierfelder, S. Bähring, and F.C. Luft for infrastructural support. This study was supported by the Competence Network for Congenital Heart Defects, Germany, funded by the Federal Ministry of Education and Research (BMBF), FKZ01G10601, the DZHK (German Centre for Cardiovascular Research) as well as support to C.A.M. from the Harvard Stem Cell Institute and the Leducq Foundation. S.A.C. is supported by the Fondation Leducq. S.A.C. and P.J.B. are supported by the National Institute for Health Research Cardiovascular BRU at the Brompton and Harefield & Harefield NHS Foundation Trust and Imperial College London and P.J.B. by Heart Research U.K. A.-K.A. was supported by a personal grant from the Deutsche Herzstiftung.

Received: April 10, 2013
Revised: May 5, 2013
Accepted: May 20, 2013
Published: June 13, 2013

Web Resources

The URLs for data presented herein are as follows:
1000 Genomes, http://browser.1000genomes.org
DECIPHER, https://decipher.sanger.ac.uk/
ECARUCA database, http://umcecaruca01.extern.umcn.nl:8080/ecaruca/ecaruca.jsp
Online Mendelian Inheritance in Man (OMIM), http://www.omim.org/
SIFT, http://sift.bii.a-star.edu.sg/
UniProt, http://www.uniprot.org/
UCSC Genome Browser, http://genome.ucsc.edu

References


